Publications

Journal of experimental & clinical cancer research : CR

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.

21-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

JAMA network open

Long-Term Survival in Patients With Advanced Melanoma.

01-08-2024

Cancers

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

26-07-2024

BMC cancer

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

23-05-2024

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

Journal for immunotherapy of cancer

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.

27-04-2024

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2024

European journal of cancer (Oxford, England : 1990)

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Journal for immunotherapy of cancer

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

31-01-2024

Cancer immunology, immunotherapy : CII

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.

27-01-2024

European journal of cancer (Oxford, England : 1990)

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

01-01-2024

Pigment cell & melanoma research

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

01-01-2024

Nature medicine

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

01-12-2023

Cancers

Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.

15-11-2023

Cancer immunology, immunotherapy : CII

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

01-11-2023

Cancer discovery

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

01-11-2023

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

01-09-2023

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-08-2023

International journal of cancer

Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.

15-07-2023

Journal for immunotherapy of cancer

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

01-07-2023

The Lancet. Oncology

Adjuvant immune checkpoint blockade revisited.

01-07-2023

International journal of cancer

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

15-06-2023

European journal of cancer (Oxford, England : 1990)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

01-06-2023

European journal of immunology

Acidity-mediated induction of FoxP3⁺ regulatory T cells.

01-06-2023

Cancer chemotherapy and pharmacology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

01-06-2023

Nature medicine

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

01-06-2023

Journal of immunotherapy (Hagerstown, Md. : 1997)

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

01-06-2023

Nature reviews. Clinical oncology

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.

01-06-2023

Cancers

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

26-05-2023

The Journal of experimental medicine

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

01-05-2023

European journal of cancer (Oxford, England : 1990)

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

01-05-2023

Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.

18-04-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Cancer research communications

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

01-04-2023

Immuno-oncology technology

Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

01-03-2023

European journal of cancer (Oxford, England : 1990)

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

01-03-2023

British journal of cancer

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

01-03-2023

Cardiovascular and interventional radiology

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

01-03-2023

Cancers

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

28-02-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Melanoma research

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

01-02-2023

Cancers

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

07-01-2023

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Long-Term Survival in Patients With Advanced Melanoma.

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

Adjuvant immune checkpoint blockade revisited.

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

Acidity-mediated induction of FoxP3+ regulatory T cells.

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

This site uses cookies

Acidity-mediated induction of FoxP3⁺ regulatory T cells.